Candel Therapeutics' Significant Updates Ahead of Medical Meeting

Candel Therapeutics Makes Mark at Upcoming Medical Conference

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a clinical-stage biopharmaceutical company, is making waves with its groundbreaking research in cancer immunotherapy. The Company will showcase its innovative enLIGHTEN™ Discovery Platform, coupled with compelling data from the CAN-2409 (aglatimagene besadenovec) program focusing on non-small cell lung cancer (NSCLC), through poster presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting.

Key Presentations Highlighting Innovations in Cancer Therapy

Candel will present two posters showcasing their advancements in the field of cancer treatment, demonstrating their commitment to providing innovative solutions to tackle daunting health challenges. This engaging event, set to take place over several days, offers a platform for experts in the field to discuss novel immunotherapy approaches.

Poster Presentations

The first poster presentation titled 'Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering' will delve into the intersection of technology and medicine. Dr. Anne Diers, the Vice President of Research at Candel Therapeutics, will lead the presentation, highlighting significant study findings and the potential impact on cancer treatment protocols.

The second poster, presented by Dr. Daniel H. Sterman from NYU Langone Medical Center, will explore an 'Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC'. This pivotal research provides insights into how tailored therapies can enhance patient outcomes in challenging cancer cases.

Engaging Discussions on Cancer Immunotherapy

As part of the event, Dr. Paul Peter Tak, the President and CEO of Candel Therapeutics, will discuss the promising results from the Phase 3 clinical trial of CAN-2409. The presentation will focus on combining CAN-2409 with standard care radiation therapy for the treatment of newly diagnosed localized prostate cancer. This renowned panel is expected to address pivotal themes in cancer immunotherapy, exploring both the potential and challenges facing the development of the next generation of cancer therapeutics.

About Candel Therapeutics

Candel is dedicated to pioneering effective cancer therapies through innovative research in multimodal biological immunotherapies. Their primary platform revolves around advanced therapeutic approaches using genetically modified adenovirus and herpes simplex virus constructs. Currently, CAN-2409 stands as a frontrunner in their portfolio, showcasing promising results from recent trials. The Company’s strategic focus has generated excitement as they aim to address various cancers, including non-small cell lung cancer and pancreatic ductal adenocarcinoma.

Innovative Therapies Leading the Way

Candel Therapeutics is also advancing another notable product candidate, CAN-3110 (linoserpaturev), which is undergoing a phase 1b clinical trial in patients with recurrent high-grade glioma. Utilizing an innovative approach, CAN-3110 has garnered attention due to its distinct mechanism and promising initial results. The continuous commitment to research and development places Candel in a pivotal position to contribute significantly to the cancer therapy landscape.

The enLIGHTEN™ Discovery Platform, a vital component of their research, exemplifies their strength in utilizing human biology and advanced data analytics to create innovative therapies tailored for solid tumors. This systematic approach not only enhances their research capabilities but also positions Candel as a key player in the biopharmaceutical sector.

Investor and Media Relations

Candel Therapeutics recognizes the importance of keeping communication channels open. Interested parties can reach out to Theodore Jenkins, Vice President of Investor Relations, and Ben Shannon for media inquiries. Their proactive stance on investor and media relations reflects their dedication to transparency and engagement.

Frequently Asked Questions

What is the focus of Candel Therapeutics?

Candel Therapeutics focuses on developing multimodal biological immunotherapies aimed at helping patients fight cancer.

What products are highlighted at the SITC meeting?

The Company will present data on CAN-2409 for non-small cell lung cancer and localized prostate cancer, as well as insights from their enLIGHTEN™ Discovery Platform.

Who presents at the SITC Annual Meeting on behalf of Candel?

Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, the President and CEO of Candel Therapeutics, will lead a presentation at the event.

What is CAN-3110?

CAN-3110 is another product candidate from Candel's HSV platform, currently in an ongoing phase 1b clinical trial for recurrent high-grade glioma.

How can investors and media contact Candel Therapeutics?

Investors can reach Theodore Jenkins at tjenkins@candeltx.com, and media inquiries can be directed to Ben Shannon at CandelPR@icrhealthcare.com.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.